Search results
Results from the WOW.Com Content Network
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. [1] It acts against interleukin 31 (IL-31), [2] which is a cytokine involved in causing itchiness (pruritus). [2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3]
Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...
Cefovecin is a broad-spectrum, third-generation cephalosporin antibiotic administered by subcutaneous injection. [4] It is used to treat skin and soft tissue infections in dogs and cats. [4] The antimicrobial effects last for 14 days following administration. [5]
Vaccination of dogs is the practice of animal vaccination applied to dogs. Programs in this field have contributed both to the health of dogs and to the public health . In countries where routine rabies vaccination of dogs is practiced, for example, rabies in humans is reduced to a very rare event.
More than 3,600 cases of debilitating dog health problems caused by the medication were reported between January 2023 and March 2024, the FDA said in the cautionary letter, published Monday.
Subcutaneous: Subcutaneous injections are given at a 45-degree angle, usually in the thigh (for babies under the age of 12 months) or upper-outer triceps area for people over 12 months. The MMR ...
Side effects from intra-articular administration can include joint pain, swelling, lameness, and, rarely, infection of the joint. Intramuscular injection can cause dose-dependent inflammation and bleeding, since PSGAG is an analogue of the anticoagulant heparin. [4] In dogs, this may manifest as bleeding from the nose or as bloody stools. [7]
Maropitant (INN; [3] brand name: Cerenia, used as maropitant citrate , is a neurokinin-1 (NK 1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [4] [5] and in 2012, for cats. [6]